Search

Your search keyword '"Tjulandin, Sergei A."' showing total 4 results
Start Over Author "Tjulandin, Sergei A." Journal journal of thoracic oncology
4 results on '"Tjulandin, Sergei A."'

1. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Author

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Published
2016
Full Text
View/download PDF

3. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Author

Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A., Shen, Robert, Tjulandin, Sergei A., Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G., and Lehmann, Frédéric F.

Abstract

Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially expressed antigen of melanoma (PRAME) tumor antigen is expressed in two-thirds of NSCLC and offers an attractive target for antigen-specific immunization. A phase I dose escalation study assessed the safety and immunogenicity of a PRAME immunotherapeutic consisting of recombinant PRAME plus proprietary immunostimulant AS15 in patients with surgically resected NSCLC (NCT01159964).

Published
2024
Full Text
View/download PDF

4. ctDNA Determination of EGFRMutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

Author

Reck, Martin, Hagiwara, Koichi, Han, Baohui, Tjulandin, Sergei, Grohé, Christian, Yokoi, Takashi, Morabito, Alessandro, Novello, Silvia, Arriola, Edurne, Molinier, Olivier, McCormack, Rose, Ratcliffe, Marianne, and Normanno, Nicola

Abstract

To offer patients with EGFRmutation–positive advanced NSCLC appropriate EGFR tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic samples are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for EGFRmutation testing.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results